Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

TCT 2021 | ESH CML/MPNs 2021: what to expect?

Ruben Mesa • 17 Feb 2021
TCT 2021
Chronic Myeloid Leukemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the upcoming 2nd How to Diagnose and Treat CML/MPN meeting, an international virtual European School of Hematology (ESH) meeting which will translate key updates in the treatment and management of chronic myeloid leukemia and myeloproliferative neoplasms. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

MPN Channel VJHemOnc banner, with Claire Harrison, Ruben Mesa, Lucia Masarova, Naveen Pemmaraju

More from Ruben Mesa

Using symptom assessment tools to improve MPN care
2:02
Using symptom assessment tools to improve MPN care
Ruben Mesa • 2 Oct 2026
Can treatment-free remission become a reality in polycythemia vera?
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
How meaningful benefit in MPNs could evolve over the next five years
2:04
How meaningful benefit in MPNs could evolve over the next five years
Ruben Mesa • 2 Oct 2026
Insights into the evolving treatment landscape for MPNs: current state and future directions
2:22
Insights into the evolving treatment landscape for MPNs: current state and future directions
Ruben Mesa • 12 Jun 2026

Related Videos

Using symptom assessment tools to improve MPN care
2:02
Using symptom assessment tools to improve MPN care
Ruben Mesa • 2 Oct 2026
Can treatment-free remission become a reality in polycythemia vera?
1:34
Can treatment-free remission become a reality in polycythemia vera?
Ruben Mesa • 2 Oct 2026
When to switch JAK inhibitor therapy in myelofibrosis
1:08
When to switch JAK inhibitor therapy in myelofibrosis
John Mascarenhas • 1 Oct 2026
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
1:36
Long-term spleen response with combination therapy in myelofibrosis: MANIFEST-2
John Mascarenhas • 1 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals